Kymera Therapeutics KYMR · NASDAQ
$108.07 +3.14% (+$3.29)
Summary
23 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $124.5M against $82.2M.
- Analysts expect revenue to grow by 167% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 5.8% a year over the last 3 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 2.9% a year over 5 years. Over the last 3 years it fell by 5.8% a year. For the next fiscal year analysts expect revenue to grow by 167%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $299.7M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 24
- Hold 3
- Sell 0
Today's price within the analysts' price targets
The average target of $138.07 is 28% above today's price. 89% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.